Investors

The need for radically different agents in the fight against untreatable infections has never been greater. Given the typical attrition rate of drug development programmes it is clear that there are too few antimicrobial resistance (AMR) innovations currently in development. The urgency of the situation is reflected in the emergence of government-level initiatives to incentivise innovators and to ensure that effective antibacterials are valued appropriately; and recent deals demonstrate that certain major pharmaceutical companies are seeking assets in this space.

What it means to be a MetalloBio investor:

‍An investor provides the vital capital required to accelerate MetalloBio through critical pre-clinical development and into Phase 1 human trials. 
Our investor base ranges from individual angels and angel networks (like Oxford Technology Management) through to mission-driven retail investors engaged via crowdfunding campaigns.
‍
Investors back MetalloBio to capture a dual return: achieving potentially significant high-growth financial rewards as we de-risk our drug candidate pipeline toward clinical use, while simultaneously funding the 'thin line' of defense against the global threat of AMR.